Second line chemotherapy for metastatic colorectal carcinoma

Gebbia,; Testa, Antonio; Cannata, G; Tirrito, M.; Longo, Ana Luiza Bomfim; Sciumè, C; Valdesi, Matteo; Salamone, Giuseppe; Gebbia, N.; Leo, Paul

doi:10.3892/or.3.5.867

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In drug re-purposing studies, LND was found to have anti-cancer activity by affecting bioenergetic homeostasis, including the glycolytic pathway, through targeting HK2 via currently unclear mechanisms[ 173 ]. LND showed promising therapeutic efficacy by inhibiting cell proliferation, migration, invasion, cell cycle progression, and increasing chemosensitivity in HCC, CCA, and CRC cell lines, as well as in a hamster CCA model[ 174 - 179 ]. Encouraging results were observed in a clinical trial recruiting patients with GC, showing improved overall response rate and duration of disease progression[ 174 ].…”

Section: Unlocking the Potential Of Glucose Metabolism Targets In Gi ...mentioning

confidence: 99%

“…Encouraging results were observed in a clinical trial recruiting patients with GC, showing improved overall response rate and duration of disease progression[ 174 ]. Reversely, it was reported that administration of LND was ineffective and toxic in clinical trials recruiting patients with CRC[ 178 , 179 ].…”

Section: Unlocking the Potential Of Glucose Metabolism Targets In Gi ...mentioning

confidence: 99%

See 1 more Smart Citation

Bioenergetic alteration in gastrointestinal cancers: The good, the bad and the ugly

Chu¹,

Chen²,

Lai³

et al. 2023

World J Gastroenterol

View full text Add to dashboard Cite

Tumor necrosis factor-α (TNF-α) antagonists, the first biologics approved for treating patients with inflammatory bowel disease (IBD), are effective for the induction and maintenance of remission and significantly improving prognosis. However, up to one-third of treated patients show primary nonresponse (PNR) to anti-TNF-α therapies, and 23%-50% of IBD patients experience loss of response (LOR) to these biologics during subsequent treatment. There is still no recognized predictor for evaluating the efficacy of anti-TNF drugs. This review summarizes the existing predictors of PNR and LOR to anti-TNF in IBD patients. Most predictors remain controversial, and only previous surgical history, disease manifestations, drug concentrations, antidrug antibodies, serum albumin, some biologic markers, and some genetic markers may be potentially predictive. In addition, we also discuss the next steps of treatment for patients with PNR or LOR to TNF antagonists. Therapeutic drug monitoring plays an important role in treatment selection. Dose escalation, combination therapy, switching to a different anti-TNF drug, or switching to a biologic with a different mechanism of action can be selected based on the concentration of the drug and/or antidrug antibodies.

show abstract

Section: Unlocking the Potential Of Glucose Metabolism Targets In Gi ...mentioning

confidence: 99%

Section: Unlocking the Potential Of Glucose Metabolism Targets In Gi ...mentioning

confidence: 99%

Bioenergetic alteration in gastrointestinal cancers: The good, the bad and the ugly

Chu¹,

Chen²,

Lai³

et al. 2023

World J Gastroenterol

View full text Add to dashboard Cite

show abstract

Second line chemotherapy for metastatic colorectal carcinoma

Cited by 1 publication

References 0 publications

Bioenergetic alteration in gastrointestinal cancers: The good, the bad and the ugly

Bioenergetic alteration in gastrointestinal cancers: The good, the bad and the ugly

Contact Info

Product

Resources

About